Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Aptevo Therapeutics Inc (APVO)

Aptevo Therapeutics Inc (APVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 84,470
  • Shares Outstanding, K 4,894
  • Annual Sales, $ 4,310 K
  • Annual Income, $ -17,750 K
  • 60-Month Beta 7.07
  • Price/Sales 19.72
  • Price/Cash Flow N/A
  • Price/Book 5.82
Trade APVO with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -1.48
  • Number of Estimates 2
  • High Estimate -1.16
  • Low Estimate -1.79
  • Prior Year -2.15
  • Growth Rate Est. (year over year) +31.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.55 +11.00%
on 08/18/21
19.10 -9.63%
on 09/02/21
+1.26 (+7.88%)
since 08/17/21
3-Month
15.55 +11.00%
on 08/18/21
29.28 -41.05%
on 06/18/21
-11.02 (-38.97%)
since 06/17/21
52-Week
6.17 +179.74%
on 10/28/20
60.00 -71.23%
on 11/09/20
+9.51 (+122.71%)
since 09/17/20

Most Recent Stories

More News
Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 1 study showed some patients with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) achieved a remission with APVO436 after failing 1-8 lines of prior therapiesData was published...

APVO : 17.26 (-0.58%)
Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights

Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and...

PFE : 43.89 (-1.30%)
APVO : 17.26 (-0.58%)
Aptevo Therapeutics' Chief Scientific Officer, Jane Gross, PhD, to Present at Upcoming Cambridge Health Institute PEGS Virtual Conference

SEATTLE, WA / ACCESSWIRE / July 16, 2021 /aEURAptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on...

APVO : 17.26 (-0.58%)
Aptevo Therapeutics' Scientists to Present At Virtual Cell Engager Summit

SEATTLE, WA / ACCESSWIRE / June 30, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its...

APVO : 17.26 (-0.58%)
Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index

SEATTLE, WA / ACCESSWIRE / June 29, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its...

APVO : 17.26 (-0.58%)
Aptevo Therapeutics Inc. (APVO) Moves 8.7% Higher: Will This Strength Last?

Aptevo Therapeutics Inc. (APVO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price...

APVO : 17.26 (-0.58%)
Aptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid Leukemia

Initiates Multi-Center, Multi-Arm Trial Using Active Dose Identified in the Dose Escalation Phase of the Trial

APVO : 17.26 (-0.58%)
Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid Leukemia

Dose Escalation Study of APVO436 Shows Favorable Safety Profile and No Severe Neutropenia, a Potentially Life-threatening Side Effect, Reported in a Significant Number of Patients Receiving CD123-Targeting...

APVO : 17.26 (-0.58%)
Hemophilia Drugs Market Size 2021 | Is Expected to Progress at a CAGR of 6% and Reach USD 15,830 Million by the end of 2025

The global "hemophilia drugs market" is expected to gain from increasing cases of gene mutation. Fortune Business Insights recently published a report, titled "Hemophilia Drugs Market Size, Share and Global...

APVO : 17.26 (-0.58%)
CSLLY : 112.3400 (-0.17%)
PFE : 43.89 (-1.30%)
Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting

SEATTLE, WA / ACCESSWIRE / April 9, 2021 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary...

APVO : 17.26 (-0.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics...

See More

Key Turning Points

3rd Resistance Point 18.23
2nd Resistance Point 17.95
1st Resistance Point 17.61
Last Price 17.26
1st Support Level 16.98
2nd Support Level 16.70
3rd Support Level 16.36

See More

52-Week High 60.00
Fibonacci 61.8% 39.44
Fibonacci 50% 33.08
Fibonacci 38.2% 26.73
Last Price 17.26
52-Week Low 6.17

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar